Bajaj Healthcare Q3 FY26: ₹161 Cr Sales, EPS ₹4.96 → Annualised ₹19.8 | Debt Falling, But Working Capital Doing Yoga
1. At a Glance – Pharma Company or Financial Thriller?
Bajaj Healthcare is like that Bollywood character who disappears in interval and comes back in the second half with a beard, redemption arc, and questionable decisions. One year it’s posting losses, next year it’s suddenly profitable, raising equity, launching new molecules, entering opium processing (yes, you read that right), and casually telling investors, “Relax bro, everything under control.”
This is not your typical boring pharma company selling Crocin and sleeping peacefully. This is a company juggling APIs, formulations, CDMO contracts, peptide synthesis, oncology ambitions, and… government-approved opium extraction.
Revenue is growing again. Margins are stabilizing. Debt is reducing. But working capital is behaving like a teenager with a credit card—completely out of control.
So the real question is: Is this a turnaround story… or just a temporary patch-up before the next drama episode?
2. Introduction – The Comeback Kid (or Just Good Lighting?)
Let’s rewind.
Bajaj Healthcare had a rough phase. Losses in FY24, negative PAT, operational hiccups. Investors who bought during the “pharma boom” probably felt like they boarded a Rajdhani Express that suddenly became a passenger train.
Then FY25 happened.
Suddenly:
Profit turnaround
New CDMO contracts
Acquisition of Genrx Pharma
New drug launches
Equity infusion
Debt repayment
Basically, management pressed Ctrl + Alt + Restart.
Now Q3 FY26 shows:
Sales: ₹161 Cr
PAT: ₹16 Cr
EPS: ₹4.96
That’s not bad.
But here’s the catch:
Stock is still down ~57% in 1 year
Promoter holding is falling
Working capital cycle is exploding
So the market is basically saying: “Nice comeback… but we’ve seen your past, beta.”
Now the real debate: Is Bajaj Healthcare genuinely improving… or just temporarily looking good after a haircut?
3. Business Model – WTF Do They Even Do?
Imagine a pharma company that refuses to pick a lane.
That’s Bajaj Healthcare.
They do:
APIs (Active Pharma Ingredients)
Formulations (tablets, capsules)
Nutraceuticals
CDMO (contract manufacturing)
Intermediates
Oncology drugs
Peptide synthesis
Opium extraction (government approved!)
Yes… opium.
Core Segments:
API Business (Backbone)
Majority revenue contributor
Supplies bulk drugs globally
Faces China competition
Formulations (High Margin Aspirant)
Growing segment
Focus on exports
CDMO (Future Hope)
Long-term contracts
Predictable revenue
Alkaloid / Opium Processing
Highly regulated
High-margin niche
Less competition
What makes it interesting?
Backward integration
60+ export countries
550+ clients
Government-linked business
But also:
Highly fragmented focus
Execution risk
Regulatory dependency
So the real question: Is this diversification… or distraction?
4. Financials Overview – Numbers Don’t Lie (But They Do Confuse)
